Zoetis Secures EU Nod for Poultry Vaccine Amid Rising Disease Outbreaks
Event summary
- Zoetis received European Commission marketing authorization for Poulvac® Procerta® HVT-ND vaccine on July 7, 2026.
- The vaccine protects chickens against Newcastle disease and Marek’s disease with a single dose.
- Approval unlocks export opportunities for poultry producers in Southeast Asia where the vaccine is already approved.
- This is the third Poulvac Procerta product authorized in Europe, following HVT-IBD (2025) and HVT-IBD-ND.
The big picture
Zoetis' latest EU approval strengthens its position in the animal health sector, particularly as poultry producers face increasing disease threats. The company's HVT vector platform has a proven global track record, and this authorization could enhance its competitive edge against other veterinary vaccine providers. With rising concerns over Newcastle disease outbreaks in Europe, demand for effective vaccination solutions is likely to grow.
What we're watching
- Market Expansion
- How the EU approval will affect Zoetis' revenue growth in European and Southeast Asian poultry markets.
- Disease Control
- Whether this vaccine can help mitigate recent Newcastle disease outbreaks across Germany, Spain, and Poland.
- Competitive Positioning
- The pace at which Zoetis can expand its Poulvac Procerta portfolio to maintain leadership in poultry vaccines.
Related topics